ELEVATED TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) BIOLOGICAL-ACTIVITY IN PSORIATIC SKIN-LESIONS

被引:370
作者
ETTEHADI, P
GREAVES, MW
WALLACH, D
ADERKA, D
CAMP, RDR
机构
[1] WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL
[2] UNIV LEICESTER,DIV DERMATOL,LEICESTER LE1 7RH,ENGLAND
关键词
TUMOR NECROSIS FACTOR; PSORIASIS; SOLUBLE TNF RECEPTORS;
D O I
10.1111/j.1365-2249.1994.tb06244.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Lesions of the common inflammatory skin disease psoriasis are characterized by epidermal hyperproliferation, leucocyte adhesion molecule expression and leucocyte infiltration. The local release of proinflammatory cytokines, such as TNF-alpha, may play an important role in the induction of these events. We have, therefore, analysed aqueous extracts of lesional and uninvolved (clinically normal) stratum corneum for the presence of TNF-alpha immunoreactivity and biological activity. TNF-alpha immunoreactivity and bioactivity were consistently higher in lesional compared with uninvolved samples. By using an anti-TNF-alpha neutralizing antibody it was demonstrated that the biological activity measured was due to the presence of TNF-alpha alone. Concentrations of soluble TNF receptors (p55 and p75) were also higher in lesional stratum corneum extracts, with the p55 form predominating. The plasma of psoriatic patients was also found to contain elevated concentrations of soluble p55 compared with normal controls. These results confirm the presence of immunoreactive TNF-alpha and, for the first time, conclusively demonstrate TNF-alpha biological activity and quantifiable concentrations of soluble TNF receptors (p55 and p75) in lesional psoriatic samples. TNF-alpha recovery from stratum corneum probably reflects synthesis in deeper, viable layers, where it is likely to exert its biological effects. Local and systemic release of soluble TNF receptors, in particular p55, may serve to regulate the effects of TNF-alpha in psoriasis.
引用
收藏
页码:146 / 151
页数:6
相关论文
共 23 条
[1]  
ADERKA D, 1991, CANCER RES, V51, P5602
[2]   MONOCLONAL-ANTIBODIES TO SOLUBLE HUMAN TNF RECEPTOR (TNF BINDING-PROTEIN) ENHANCE ITS ABILITY TO BLOCK TNF TOXICITY [J].
ADOLF, GR ;
FRUHBEIS, B .
CYTOKINE, 1992, 4 (03) :180-184
[3]   BIOLOGY OF MULTIFUNCTIONAL CYTOKINES - IL-6 AND RELATED MOLECULES (IL-1 AND TNF) [J].
AKIRA, S ;
HIRANO, T ;
TAGA, T ;
KISHIMOTO, T .
FASEB JOURNAL, 1990, 4 (11) :2860-2867
[4]   CUTANEOUS LYMPHOCYTE TRAFFICKING IN THE INFLAMMATORY DERMATOSES [J].
BARKER, JNWN ;
MACDONALD, DM .
BRITISH JOURNAL OF DERMATOLOGY, 1992, 126 (03) :211-215
[5]  
BARKER JNWN, 1992, SPRINGER SEMIN IMMUN, V13, P355
[6]   IDENTIFICATION OF 2 TYPES OF TUMOR-NECROSIS-FACTOR RECEPTORS ON HUMAN CELL-LINES BY MONOCLONAL-ANTIBODIES [J].
BROCKHAUS, M ;
SCHOENFELD, HJ ;
SCHLAEGER, EJ ;
HUNZIKER, W ;
LESSLAUER, W ;
LOETSCHER, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (08) :3127-3131
[7]   INDUCTION OF ICAM-1 EXPRESSION BY EPIDERMAL-KERATINOCYTES VIA A PARACRINE PATHWAY POSSIBLY INVOLVING DERMAL DENDRITIC CELLS [J].
BRUYNZEEL, I ;
NICKOLOFF, BJ ;
VANDERRAAIJ, EMH ;
BOORSMA, DM ;
STOOF, TJ ;
WILLEMZE, R .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 1992, 284 (04) :250-252
[8]  
CAMP RDR, 1992, TXB DERMATOLOGY, P1391
[9]  
COLDITZ IG, 1992, IMMUNOLOGY, V76, P272
[10]  
ENGELMANN H, 1989, J BIOL CHEM, V264, P11974